- Home
- CTSO
as 12-18-2024 12:35pm EST
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 48.2M | IPO Year: | N/A |
| Target Price: | $4.67 | AVG Volume (30 days): | 135.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.70 - $1.97 | Next Earning Date: | 11-07-2024 |
| Revenue: | $37,739,531 | Revenue Growth: | 1.80% |
| Revenue Growth (this year): | 8.08% | Revenue Growth (next year): | 12.80% |
Stock Insider Trading Activity of Cytosorbents Corporation (CTSO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MARIANI PETER J | CTSO | Chief Financial Officer | Dec 13 '24 | Buy | $0.96 | 20,000 | $19,294.00 | 401,363 | |
| MARIANI PETER J | CTSO | Chief Financial Officer | Dec 11 '24 | Buy | $0.89 | 31,363 | $27,974.84 | 401,363 |
Latest Cytosorbents Corporation News
CTSO Breaking Stock News: Dive into CTSO Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
Zacks Small Cap Research
6 days ago
CTSO: CytoSorbents Announces Rights Offering Which has the Potential to Substantially Increase Available Liquidity
GlobeNewswire
9 days ago
CytoSorbents Announces Rights Offering
GlobeNewswire
22 days ago
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference
Zacks Small Cap Research
a month ago
CTSO: CytoSorbents Potential for High Margin Revenue Growth Supports Price Target of $4.00
Simply Wall St.
a month ago
Several Insiders Invested In Cytosorbents Flagging Positive News
GlobeNewswire
a month ago
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
GuruFocus.com
a month ago
CytoSorbents Corp (CTSO) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Improved ...
Compare CTSO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CTSO Cytosorbents Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.